Par Pharmaceutical Begins Shipment of Generic Atacand®
WOODCLIFF LAKE, N.J., May 22, 2013
WOODCLIFF LAKE, N.J., May 22, 2013 /PRNewswire/ -- Par Pharmaceutical
Companies, Inc. today announced that it has entered into an exclusive U.S.
supply and distribution agreement with AstraZeneca to distribute the
authorized generic version of AstraZeneca's Atacand^® (candesartan
cilexetil). Par has begun shipping 4 mg, 8 mg, 16 mg and 32 mg strengths of
candesartan cilexetil tablets. According to IMS Health data, annual U.S.
sales of Atacand^® are approximately $113 million.
Important Information About Candesartan Cilexetil Tablets
Candesartan cilexetil is an angiotensin II receptor blocker indicated for the
treatment of hypertension in adults and children 1 to < 17 years of age and
the treatment of heart failure (NYHA class II-IV). Candesartan cilexetil
reduces cardiovascular death and heart failure hospitalization.
Candesartan cilexetil is contraindicated in patients who are hypersensitive to
any component of the product. A black box warning is associated with this
product regarding fetal toxicity. When pregnancy is detected, candesartan
cilexetil should be discontinued as soon as possible. Drugs that act directly
on the rennin-angiotensin system can cause injury and death to the developing
fetus. Refer to full prescribing information for complete boxed warnings.
About Par Pharmaceutical Companies, Inc.
Par Pharmaceutical Companies, Inc. is a privately held, U.S.-based specialty
pharmaceutical company that develops, manufactures and markets high
barrier-to-entry generic drugs and niche, innovative proprietary
pharmaceuticals through its wholly-owned subsidiary's two operating divisions,
Par Pharmaceutical and Strativa Pharmaceuticals. For press release and other
company information, visit www.parpharm.com.
SOURCE Par Pharmaceutical Companies, Inc.
Contact: Stephen Mock, Par Pharmaceutical Companies, Inc., (201) 802-4033
Press spacebar to pause and continue. Press esc to stop.